Table 1.
List of clinical trials with adoptive NK cells investigated in combination with other therapeutics
| NCT number | NK cells | Combination | Malignancy | Phase | First posted (Year) | Status |
|---|---|---|---|---|---|---|
| NCT00376805 | Allogeneic NK cells | Cyclophosphamide, fludarabine | Breast cancer | 2 | 2006 | Terminated |
| NCT00625729 | Donor NK cells | Rituximab, fludarabine, cyclophosphamide | CLL, non-Hodgkin lymphoma | 1 | 2008 | Terminated |
| NCT00698009 | Haploidentical NK cells | Cyclophosphamide, fludarabine | Neuroblastoma | 2 | 2008 | Terminated |
| NCT00941928 | Haploidentical NK cells | Epratuzumab | ALL | 2 | 2009 | Terminated |
| NCT01593670 | Donor NK cells | Decitabine, vorinostat | MDS | 2 | 2012 | Completed |
| NCT02316964 | Donor NK cells | Decitabine | AML | 1 | 2014 | Completed |
| NCT02370017 | NK cell enriched lymphocytes (ANKL) | Docetaxel | Non-small cell lung cancer | 2 | 2015 | Unknown |
| NCT02734524 | Autologous NK cells | Taxol, carboplatin | Non-small cell lung cancer | 2 | 2016 | Unknown |
| NCT02843126 | NK cells | Trastuzumab | Breast cancer | 1 and 2 | 2016 | Completed |
| NCT02843204 | Allogeneic NK cells | Pembrolizumab | Multiple cancers | 1 and 2 | 2016 | Completed |
| NCT02845856 | NK cells | Cetuximab | Non-small cell lung cancer | 1 and 2 | 2016 | Completed |
| NCT02857920 | Allogeneic NK cells | Bevacizumab | Multiple cancers | 1 and 2 | 2016 | Completed |
| NCT03056339 | CD19 CAR-NK cells | Fludarabine, cyclophosphamide | ALL, CLL, non-Hodgkin lymphoma | 1 and 2 | 2017 | Recruiting |
| NCT03366064 | Haploidentical NK cells | Pemetrexed | Non-small cell lung cancer | 1 | 2017 | Completed |
| NCT03554889 | Autologous NK cells | Nimotuzumab | Multiple cancers | 1 | 2018 | Unkown |
| NCT03841110 | Allogeneic NK cells (FT500) | Nivolumab, pembrolizumab, atezolizumab, cyclophophamide, fludarabine | Multiple cancers | 1 | 2019 | Recruiting |
| NCT03937895 | Allogeneic NK cells | Pembrolizumab | Biliary tract cancer | 1 and 2 | 2019 | Recruiting |
| NCT03941262 | Autologous NK cells (SKN01) | Avelumab, pembrolizumab | Multiple cancers | 1 | 2019 | Recruiting |
| NCT03958097 | Autologous NK cells | PD-1/PD-L1 antibody | Non-small cell lung cancer | 2 | 2019 | Unknown |
| NCT04220684 | Haploidentical NK cells | Cytarabine, decitabine, fludarabine | AML, MDS | 1 | 2020 | Recruiting |
| NCT04290546 | Donor NK cells | Ipilimumab | Head and neck cancer | 1 | 2020 | Recruiting |
| NCT04558931 | Autologous NK cells | Isatuximab | MM | 2 | 2020 | Not yet recruiting |
| NCT04796675 | CD19 CAR-NK cells | Fludarabine, cyclophosphamide | ALL, CLL, non-Hodgkin lymphoma | 1 | 2021 | Recruiting |
| NCT04847466 | Irradiated PD-L1 CAR-NK cells | Pembrolizumab | Gastric or head and neck cancer | 2 | 2021 | Not yet recruiting |
| NCT04872634 | Autologous NK cells (SKN01) | Gemcitabine, cetuximab | Non-small cell lung cancer | 1 and 2 | 2021 | Not yet recruiting |